{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:52:53Z","timestamp":1787032373022,"version":"build-2736575974"},"reference-count":111,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Pleural mesothelioma is a rare cancer with an often-challenging diagnosis because of its potential to be a great mimicker of many other tumors. Among them, primary lung and breast cancers are the 2 main causes of pleural metastasis. The development and application of targeted therapeutic agents have made it even more important to achieve an accurate diagnosis. In this setting, international guidelines have recommended the use of 2 positive and 2 negative immunohistochemical biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives.\u2014<\/jats:title>\n                    <jats:p>To define the most highly specific and sensitive minimum set of antibodies for routine practice to use for the separation of epithelioid malignant mesothelioma from lung and breast metastasis and to determine the most relevant expression cutoff.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>To provide information at different levels of expression of 16 mesothelial and epithelial biomarkers, we performed a systematic review of articles published between 1979 and 2017, and we compared those data to results from the Mesothelioma Telepathology Network (MESOPATH) of the standardized panel used in routine practice database since 1998.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Our results indicate that the following panel of markers\u2014calretinin (poly)\/thyroid transcription factor 1 (TTF-1; clone 8G7G3\/1) and calretinin (poly)\/estrogen receptor-\u03b1 (ER-\u03b1; clone EP1)\u2014should be recommended; ultimately, based on the MESOPATH database, we highlight their relevance which are the most sensitive and specific panel useful to the differential diagnosis at 10% cutoff.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Highlighted by their relevance in the large cohort reported, we recommend 2 useful panels to the differential diagnosis at 10% cutoff.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2018-0457-oa","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T10:02:49Z","timestamp":1565172169000},"page":"446-456","source":"Crossref","is-referenced-by-count":22,"title":["Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies\u2014A New Proposal That May Influence Pathologic Practice"],"prefix":"10.5858","volume":"144","author":[{"given":"Nolwenn","family":"Le Stang","sequence":"first","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Burke","sequence":"additional","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetane","family":"Blaizot","sequence":"additional","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen R.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lebailly","sequence":"additional","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clin","sequence":"additional","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Galateau-Sall\u00e9","sequence":"additional","affiliation":[{"name":"From the Pleural Mesothelioma National Multicentric Registry (MESONAT), MESOPATH National Network on Mesothelioma (Ms Le Stang and Dr Galateau-Sall\u00e9), the EURACAN network (Dr Girard), and MESOBANK Clinicobiological Database and National Frozen Tissue Bank (Dr Galateau-Sall\u00e9), L\u00e9on B\u00e9rard Cancer Center, Lyon, France; the Department of Pathology, Cork University Hospital, Cork, Ireland (Dr Burke);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the MESOPATH and EURACAN networks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b01","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b02","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/oemed-2016-104119","article-title":"The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure","volume":"75","author":"Marinaccio","year":"2018","journal-title":"Occup Environ Med"},{"key":"2022042506220731100_i1543-2165-144-4-446-b03","doi-asserted-by":"crossref","unstructured":"Galateau\u2013Sall\u00e9 F , BrambillaE, CagleP, et al. Pathology of Malignant Mesothelioma: An Update of the International Mesothelioma Panel. London, England: Springer Verlag;2006:29.","DOI":"10.1007\/978-1-84628-012-2"},{"issue":"5","key":"2022042506220731100_i1543-2165-144-4-446-b04","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","article-title":"Management of malignant pleural effusions","volume":"162","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b05","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification","volume":"11","author":"Galateau\u2013Salle","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b06","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b07","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/JTO.0b013e31822f6544","article-title":"Sustained expression of steroid receptor coactivator SRC\u20132\/TIF\u20132 is associated with better prognosis in malignant pleural mesothelioma","volume":"7","author":"Jennings","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b08","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2559.2005.02331.x","article-title":"Sensitivity and specificity of immunohistochemical biomarkers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data","volume":"48","author":"King","year":"2006","journal-title":"Histopathology"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b09","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/oem.2005.023200","article-title":"The French National Mesothelioma Surveillance Program","volume":"63","author":"Goldberg","year":"2006","journal-title":"Occup Environ Med"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/modpathol.3800534","article-title":"Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three\u2013antibody immunohistochemical panel with maximal sensitivity and specificity","volume":"19","author":"Yaziji","year":"2006","journal-title":"Mod Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Mod Pathol"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/pin.12278","article-title":"Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical biomarkers in the diagnosis of metastatic breast carcinoma to the lung","volume":"65","author":"Hattori","year":"2015","journal-title":"Pathol Int"},{"issue":"16","key":"2022042506220731100_i1543-2165-144-4-446-b14","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN\u20131 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"2022042506220731100_i1543-2165-144-4-446-b15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.humpath.2014.03.006","article-title":"Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study","volume":"45","author":"Ord\u00f3\u00f1ez","year":"2014","journal-title":"Hum Pathol"},{"issue":"11","key":"2022042506220731100_i1543-2165-144-4-446-b16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jcp.37.11.1215","article-title":"Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium","volume":"37","author":"Marshall","year":"1984","journal-title":"J Clin Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/jcp.40.1.19","article-title":"Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies","volume":"40","author":"Ghosh","year":"1987","journal-title":"J Clin Pathol"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00713385","article-title":"Immunohistochemistry in the diagnosis of malignant mesothelioma","volume":"411","author":"Pfaltz","year":"1987","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00000478-198904000-00003","article-title":"The immunohistochemical diagnosis of mesothelioma: differentiation of mesothelioma and lung adenocarcinoma","volume":"13","author":"Ord\u00f3\u00f1ez","year":"1989","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b20","first-page":"20","article-title":"Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects [in French]","volume":"10","author":"Chenard-Neu","year":"1990","journal-title":"Ann Pathol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jso.2930450204","article-title":"Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies","volume":"45","author":"Tuttle","year":"1990","journal-title":"J Surg Oncol"},{"issue":"7","key":"2022042506220731100_i1543-2165-144-4-446-b22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0046-8177(90)90036-5","article-title":"Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases","volume":"21","author":"Wick","year":"1990","journal-title":"Hum Pathol"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1699-0463.1994.tb04873.x","article-title":"Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis","volume":"102","author":"Dejmek","year":"1994","journal-title":"APMIS"},{"issue":"5","key":"2022042506220731100_i1543-2165-144-4-446-b24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2559.1998.00405.x","article-title":"A comparative evaluation of immunohistochemical biomarkers for the differential diagnosis of malignant pleural tumors","volume":"32","author":"Garcia-Prats","year":"1998","journal-title":"Histopathology"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b25","first-page":"24","article-title":"Evaluation of membranous staining of mesothelioma","volume":"5","author":"King","year":"1998","journal-title":"Cell Vis"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1309\/QHCA-8594-TA7P-0DVQ","article-title":"An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma","volume":"114","author":"Brockstedt","year":"2000","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2022042506220731100_i1543-2165-144-4-446-b27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/hupa.2001.24329","article-title":"Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical biomarkers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma","volume":"32","author":"Comin","year":"2001","journal-title":"Hum Pathol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1309\/XL6K-8E62-9FLD-V8Q8","article-title":"Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies","volume":"116","author":"Roberts","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/BF03032393","article-title":"Specificity of MOC\u201331 and HBME\u20131 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages","volume":"8","author":"G\u00fcm\u00fcrd\u00fcl\u00fc","year":"2002","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"2022042506220731100_i1543-2165-144-4-446-b30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00000478-200308000-00001","article-title":"The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000478-200604000-00006","article-title":"h\u2013Caldesmon, a useful positive biomarker in the diagnosis of pleural malignant mesothelioma, epithelioid type","volume":"30","author":"Comin","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000093091","article-title":"D2\u201340: a reliable biomarker in the diagnosis of pleural mesothelioma","volume":"73","author":"M\u00fcller","year":"2006","journal-title":"Pathobiology"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","article-title":"Immunohistochemical biomarker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma","volume":"57","author":"Kushitani","year":"2007","journal-title":"Pathol Int"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00000478-198706000-00005","article-title":"Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma: a bi\u2013institutional study of 47 cases","volume":"11","author":"Otis","year":"1987","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/1097-0142(19910201)67:3<655::AID-CNCR2820670322>3.0.CO;2-J","article-title":"Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma","volume":"67","author":"Wirth","year":"1991","journal-title":"Cancer"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2559.2001.01157.x","article-title":"Combined use of novel epithelial (MOC\u201331) and mesothelial (HBME\u20131) immunohistochemical biomarkers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura","volume":"38","author":"Gonz\u00e1lez-Lois","year":"2001","journal-title":"Histopathology"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b37","first-page":"827","article-title":"Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma","volume":"141","author":"Collins","year":"1992","journal-title":"Am J Pathol"},{"issue":"12","key":"2022042506220731100_i1543-2165-144-4-446-b38","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199712000-00003","article-title":"The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat\u2013induced epitope retrieval","volume":"21","author":"Riera","year":"1997","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2559.1996.tb01393.x","article-title":"Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma","volume":"29","author":"Attanoos","year":"1996","journal-title":"Histopathology"},{"issue":"9","key":"2022042506220731100_i1543-2165-144-4-446-b40","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/00000478-199609000-00001","article-title":"Calretinin: a novel immunocytochemical biomarker for mesothelioma","volume":"20","author":"Doglioni","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2022042506220731100_i1543-2165-144-4-446-b41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/jcp.50.10.859","article-title":"HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura","volume":"50","author":"Kennedy","year":"1997","journal-title":"J Clin Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2559.1997.6020829.x","article-title":"Value of thrombomodulin immunostaining in the diagnosis of mesothelioma","volume":"31","author":"Ord\u00f3\u00f1ez","year":"1997","journal-title":"Histopathology"},{"issue":"12","key":"2022042506220731100_i1543-2165-144-4-446-b43","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/00000478-199712000-00002","article-title":"The value of antibodies 44\u20134a6, SM3, HBME\u20131, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies","volume":"21","author":"Ord\u00f3\u00f1ez","year":"1997","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/modpathol.3880018","article-title":"Value of the mesothelium\u2013associated antibodies thrombomodulin, cytokeratin 5\/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura","volume":"13","author":"Cury","year":"2000","journal-title":"Mod Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000478-200101000-00004","article-title":"Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis","volume":"25","author":"Carella","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2022042506220731100_i1543-2165-144-4-446-b46","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.5858\/2001-125-1316-IAONVC","article-title":"Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas","volume":"125","author":"Foster","year":"2001","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"2022042506220731100_i1543-2165-144-4-446-b47","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/jcp.55.9.662","article-title":"Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies","volume":"55","author":"Abutaily","year":"2002","journal-title":"J Clin Pathol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","article-title":"Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura","volume":"27","author":"Miettinen","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2022042506220731100_i1543-2165-144-4-446-b49","first-page":"559","article-title":"Expression of thrombomodulin, calretinin, cytokeratin 5\/6, D2\u201340 and WT1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma","volume":"100","author":"Comin","year":"2014","journal-title":"Tumori"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000478-199203000-00006","article-title":"Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma","volume":"16","author":"Chang","year":"1992","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2559.2005.02279.x","article-title":"The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies","volume":"48","author":"Galloway","year":"2006","journal-title":"Histopathology"},{"issue":"9","key":"2022042506220731100_i1543-2165-144-4-446-b52","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.humpath.2010.03.002","article-title":"Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter","volume":"41","author":"Tan","year":"2010","journal-title":"Hum Pathol"},{"issue":"10","key":"2022042506220731100_i1543-2165-144-4-446-b53","first-page":"929","article-title":"Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma","volume":"11","author":"Ord\u00f3\u00f1ez","year":"1998","journal-title":"Mod Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.3800259","article-title":"Utility of D2\u201340, a novel mesothelial biomarker, in the diagnosis of malignant mesothelioma","volume":"18","author":"Chu","year":"2005","journal-title":"Mod Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2559.2009.03322.x","article-title":"Caveolin\u20131 is a novel immunohistochemical biomarker to differentiate epithelioid mesothelioma from lung adenocarcinoma","volume":"55","author":"Amatya","year":"2009","journal-title":"Histopathology"},{"key":"2022042506220731100_i1543-2165-144-4-446-b56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1746-1596-5-47","article-title":"Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry","volume":"5","author":"Sandeck","year":"2010","journal-title":"Diagn Pathol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b57","first-page":"344","article-title":"Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma","volume":"146","author":"Amin","year":"1995","journal-title":"Am J Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z","article-title":"WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis","volume":"181","author":"Kumar\u2013Singh","year":"1997","journal-title":"J Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/his.13073","article-title":"Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma","volume":"70","author":"Kushitani","year":"2017","journal-title":"Histopathology"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1365-2559.1997.2150833.x","article-title":"Anti\u2013cytokeratin 5\/6: a positive biomarker for epithelioid mesothelioma","volume":"31","author":"Clover","year":"1997","journal-title":"Histopathology"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5603\/ARM.28007","article-title":"A comparative evaluation of immunohistochemical biomarkers for the differential diagnosis between malignant mesothelioma, non\u2013small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation [in Polish]","volume":"75","author":"Szczepulska-W\u00f3jcik","year":"2007","journal-title":"Pneumonol Alergol Pol"},{"issue":"10","key":"2022042506220731100_i1543-2165-144-4-446-b62","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/00000478-199810000-00006","article-title":"Value of cytokeratin 5\/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma","volume":"22","author":"Ord\u00f3\u00f1ez","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2022042506220731100_i1543-2165-144-4-446-b63","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/1097-0142(20011115)92:10<2727::AID-CNCR1627>3.0.CO;2-B","article-title":"The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas","volume":"92","author":"Tot","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/modpathol.3880483","article-title":"Expression of cytokeratin 5\/6 in epithelial neoplasms: an immunohistochemical study of 509 cases","volume":"15","author":"Chu","year":"2002","journal-title":"Mod Pathol"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b65","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.humpath.2005.01.019","article-title":"D2\u201340 and podoplanin are highly specific and sensitive immunohistochemical biomarkers of epithelioid malignant mesothelioma","volume":"36","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"Hum Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/PAS.0b013e31814faacf","article-title":"Podoplanin is a better immunohistochemical biomarker for sarcomatoid mesothelioma than calretinin","volume":"32","author":"Padgett","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2022042506220731100_i1543-2165-144-4-446-b67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.22477","article-title":"Novel biomarker D2\u201340, combined with calretinin, CEA, and TTF\u20131: an optimal set of immunodiagnostic biomarkers for pleural mesothelioma","volume":"109","author":"Mimura","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"2022042506220731100_i1543-2165-144-4-446-b68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.prp.2009.06.001","article-title":"Is D2\u201340 a useful biomarker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?","volume":"205","author":"Deniz","year":"2009","journal-title":"Pathol Res Pract"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b69","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/1097-0142(197909)44:3<937::AID-CNCR2820440322>3.0.CO;2-K","article-title":"Absence of carcinoembryonic antigen\u2013like material in mesothelioma: an immunohistochemical differentiation from other lung cancers","volume":"44","author":"Wang","year":"1979","journal-title":"Cancer"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b70","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00710235","article-title":"The use of vimentin antibodies in the diagnosis of malignant mesothelioma","volume":"406","author":"Jasani","year":"1985","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"9","key":"2022042506220731100_i1543-2165-144-4-446-b71","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1183\/09031936.93.03090997","article-title":"Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions","volume":"3","author":"al-Saffar","year":"1990","journal-title":"Eur Respir J"},{"issue":"8","key":"2022042506220731100_i1543-2165-144-4-446-b72","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/1097-0142(19850415)55:8<1679::AID-CNCR2820550812>3.0.CO;2-C","article-title":"Distinction of mesothelioma from adenocarcinoma: an immunohistochemical approach","volume":"55","author":"Battifora","year":"1985","journal-title":"Cancer"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b73","first-page":"212","article-title":"Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: An immunohistologic analysis demonstrating the value of Leu M1 antigen","volume":"123","author":"Sheibani","year":"1986","journal-title":"Am J Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b74","first-page":"291","article-title":"Carcinoembryonic antigen and milk\u2013fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung","volume":"111","author":"Tron","year":"1987","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b75","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/1097-0142(19940115)73:2<464::AID-CNCR2820730235>3.0.CO;2-#","article-title":"Carcinoembryonic antigen\u2013like reactivity in malignant mesothelioma: a comparison between different commercially available antibodies","volume":"73","author":"Dejmek","year":"1994","journal-title":"Cancer"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b76","first-page":"80","article-title":"Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas","volume":"108","author":"Corson","year":"1982","journal-title":"Am J Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00496570","article-title":"Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining","volume":"397","author":"Kwee","year":"1982","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00313028209061373","article-title":"Detection of tissue CEA\u2013like substance as an aid in the differential diagnosis of malignant mesothelioma","volume":"14","author":"Whitaker","year":"1982","journal-title":"Pathology"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/thx.40.2.91","article-title":"Comparison of tumor biomarkers in malignant mesothelioma and pulmonary adenocarcinoma","volume":"40","author":"Gibbs","year":"1985","journal-title":"Thorax"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jso.2930350107","article-title":"Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma","volume":"35","author":"Lucas","year":"1987","journal-title":"J Surg Oncol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b81","first-page":"252","article-title":"The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3)","volume":"122","author":"Szpak","year":"1986","journal-title":"Am J Pathol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b82","first-page":"421","article-title":"ME1. A monoclonal antibody that distinguishes epithelial\u2013type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies","volume":"136","author":"O'Hara","year":"1990","journal-title":"Am J Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ajcp\/94.1.18","article-title":"Expression of \u201cmyelomonocytic\u201d antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces","volume":"94","author":"Wick","year":"1990","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2022042506220731100_i1543-2165-144-4-446-b84","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/00000478-199108000-00008","article-title":"Ber\u2013EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma","volume":"15","author":"Sheibani","year":"1991","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b85","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0046-8177(93)90080-Z","article-title":"Multiple\u2013biomarker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma","volume":"24","author":"Brown","year":"1993","journal-title":"Hum Pathol"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF01606427","article-title":"Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue, part I: immunohistochemical findings","volume":"423","author":"Moch","year":"1993","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b87","first-page":"30","article-title":"Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid\u2013Schiff, monoclonal antibodies B72.3, and Leu M1","volume":"133","author":"Warnock","year":"1988","journal-title":"Am J Pathol"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b88","first-page":"427","article-title":"Immunohistochemical analysis of pulmonary and pleural neoplasms with monoclonal antibodies B72.3 and CSLEX\u20131","volume":"58","author":"Koukoulis","year":"1990","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"issue":"5","key":"2022042506220731100_i1543-2165-144-4-446-b89","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0046-8177(94)90115-5","article-title":"p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens","volume":"25","author":"Cagle","year":"1994","journal-title":"Hum Pathol"},{"issue":"5","key":"2022042506220731100_i1543-2165-144-4-446-b90","first-page":"931","article-title":"Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma","volume":"135","author":"Jordon","year":"1989","journal-title":"Am J Pathol"},{"issue":"9","key":"2022042506220731100_i1543-2165-144-4-446-b91","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00000478-200004000-00016","article-title":"Value of thyroid transcription factor\u20131, E\u2013cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma","volume":"24","author":"Ord\u00f3\u00f1ez","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2022042506220731100_i1543-2165-144-4-446-b92","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jcp.43.3.213","article-title":"BerEP4: new monoclonal antibody which distinguishes epithelia from mesothelial","volume":"43","author":"Latza","year":"1990","journal-title":"J Clin Pathol"},{"issue":"11","key":"2022042506220731100_i1543-2165-144-4-446-b93","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0344-0338(11)80900-3","article-title":"The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma","volume":"190","author":"Grove","year":"1994","journal-title":"Pathol Res Pract"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b94","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00000478-199206000-00007","article-title":"Immunoreactivity for BEREP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas","volume":"16","author":"Gaffey","year":"1992","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2022042506220731100_i1543-2165-144-4-446-b95","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/jcp.48.7.626","article-title":"632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material","volume":"48","author":"Edwards","year":"1995","journal-title":"J Clin Pathol"},{"issue":"4","key":"2022042506220731100_i1543-2165-144-4-446-b96","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2559.2000.00770.x","article-title":"HBME\u20131, MOC\u201331, WT1 and calretinin: an assessment of recently described biomarkers for mesothelioma and adenocarcinoma","volume":"36","author":"Oates","year":"2000","journal-title":"Histopathology"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b97","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0046-8177(98)90227-1","article-title":"Value of the MOC\u201331 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma","volume":"29","author":"Ord\u00f3\u00f1ez","year":"1998","journal-title":"Hum Pathol"},{"issue":"7","key":"2022042506220731100_i1543-2165-144-4-446-b98","first-page":"716","article-title":"AntiMOC31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel","volume":"10","author":"Sosolik","year":"1997","journal-title":"Mod Pathol"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3835(97)00466-7","article-title":"TTF1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung","volume":"124","author":"Di Loreto","year":"1998","journal-title":"Cancer Lett"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0046-8177(99)90096-5","article-title":"Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma","volume":"30","author":"Khoor","year":"1999","journal-title":"Hum Pathol"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b101","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.anndiagpath.2004.08.003","article-title":"TTF\u20131 and surfactant\u2013B as co\u2013adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma","volume":"8","author":"Bakir","year":"2004","journal-title":"Ann Diagn Pathol"},{"issue":"7","key":"2022042506220731100_i1543-2165-144-4-446-b102","first-page":"957","article-title":"The value of immunohistochemical expression of TTF\u20131, CK7 and CK20 in the diagnosis of primary and secondary lung carcinomas","volume":"29","author":"Al-Zahrani","year":"2008","journal-title":"Saudi Med J"},{"issue":"1","key":"2022042506220731100_i1543-2165-144-4-446-b103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2009.06.014","article-title":"and thyroid transcription factor\u20131 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma","volume":"41","author":"Bishop","year":"2010","journal-title":"Hum Pathol"},{"issue":"2","key":"2022042506220731100_i1543-2165-144-4-446-b104","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/jclinpath-2015-203184","article-title":"An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma","volume":"69","author":"Klebe","year":"2016","journal-title":"J Clin Pathol"},{"issue":"14","key":"2022042506220731100_i1543-2165-144-4-446-b105","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/nar\/29.14.2905","article-title":"Estrogen receptor interaction with estrogen response elements","volume":"29","author":"Klinge","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"pt 3","key":"2022042506220731100_i1543-2165-144-4-446-b106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.mce.2015.11.028","article-title":"Estrogen action: receptors, transcripts, cell signaling, and non\u2013coding RNAs in normal physiology and disease","volume":"418","author":"Klinge","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b107","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/PAI.0b013e31818a9d3a","article-title":"Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry","volume":"16","author":"Yaziji","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"36","key":"2022042506220731100_i1543-2165-144-4-446-b108","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1200\/JCO.2012.44.6955","article-title":"Prognostic\/predictive immunohistochemistry assays for estrogen receptor\u2013positive breast cancer: back to the future [comment]?","volume":"30","author":"Bhargava","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"2022042506220731100_i1543-2165-144-4-446-b109","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"issue":"6","key":"2022042506220731100_i1543-2165-144-4-446-b110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/his.13321","article-title":"Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours","volume":"71","author":"Yoshimura","year":"2017","journal-title":"Histopathology"},{"issue":"Suppl 1","key":"2022042506220731100_i1543-2165-144-4-446-b111","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.lungcan.2005.03.017","article-title":"Implications of P16\/CDKN2A deletion in pleural mesotheliomas","volume":"49","author":"Ladanyi","year":"2005","journal-title":"Lung Cancer"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/4\/446\/2918431\/arpa_2018-0457-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/4\/446\/2918431\/arpa_2018-0457-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:02Z","timestamp":1764790862000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/4\/article-p446.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,8,7]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2018-0457-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]}}}